161 related articles for article (PubMed ID: 29441972)
1. An investigation of visual hallucinations associated with voriconazole administration to patients with hematological malignancies.
Sakurada H; Yasuhara K; Kato K; Asano S; Yoshida M; Yamamura M; Tachi T; Teramachi H
Pharmazie; 2016 Nov; 71(11):660-664. PubMed ID: 29441972
[TBL] [Abstract][Full Text] [Related]
2. Visual disturbance or central symptom like hallucination in patients treated voriconazole: report of six cases.
Kato H; Hagihara M; Hamada Y; Koizumi Y; Nishiyama N; Yamagishi Y; Matsuura K; Mikamo H
Jpn J Antibiot; 2016 Sep; 69(3):143-150. PubMed ID: 30226950
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole-associated visual disturbances and hallucinations.
Bayhan GI; Garipardic M; Karaman K; Akbayram S
Cutan Ocul Toxicol; 2016 Mar; 35(1):80-2. PubMed ID: 25799212
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients.
Imataki O; Yamaguchi K; Uemura M; Fukuoka N
Transpl Infect Dis; 2018 Aug; 20(4):e12886. PubMed ID: 29570914
[TBL] [Abstract][Full Text] [Related]
5. Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population.
Imataki O; Ohnishi H; Kitanaka A; Kubota Y; Ishida T; Tanaka T
Int J Hematol; 2008 Jul; 88(1):3-6. PubMed ID: 18574651
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
[TBL] [Abstract][Full Text] [Related]
7. Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan.
Koh H; Hino M; Ohta K; Iino M; Urase F; Yamaguchi M; Yamanouchi J; Usui N; Yoshida M; Tanimoto M; Ohyashiki K; Urabe A; Tamura K; Kanamaru A; Masaoka T
J Infect Chemother; 2013 Dec; 19(6):1126-34. PubMed ID: 23813092
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole-induced musical hallucinations.
Agrawal AK; Sherman LK
Infection; 2004 Oct; 32(5):293-5. PubMed ID: 15624894
[TBL] [Abstract][Full Text] [Related]
9. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
[TBL] [Abstract][Full Text] [Related]
10. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of transient receptor potential melastatin 1 correlate with voriconazole-related visual adverse events.
Jiang YK; Wang RY; Wang X; Zhao HZ; Zhou LH; Huang LP; Yip CW; Cheng JH; Que CX; Jiang C; Zhu LP
Mycoses; 2020 Jun; 63(6):579-587. PubMed ID: 32222082
[TBL] [Abstract][Full Text] [Related]
13. Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database.
Kato H; Shiraishi C; Hagihara M; Mikamo H; Iwamoto T
Sci Rep; 2024 May; 14(1):12519. PubMed ID: 38822123
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
15. Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies.
Perreault S; McManus D; Anderson A; Lin T; Ruggero M; Topal JE
J Oncol Pharm Pract; 2019 Sep; 25(6):1305-1311. PubMed ID: 29996736
[TBL] [Abstract][Full Text] [Related]
16. [Otomastoiditis due to Scedosporium apiospermum. Hallucinations as an adverse reaction to voriconazol].
Fuster-Escrivá B; Chanzá-Aviñó M; Concepción Gimeno-Cardona
Rev Iberoam Micol; 2019; 36(3):165-166. PubMed ID: 31303483
[No Abstract] [Full Text] [Related]
17. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment?
Cherif H; Kalin M; Björkholm M
Eur J Haematol; 2006 Oct; 77(4):288-92. PubMed ID: 16856930
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
[TBL] [Abstract][Full Text] [Related]
20. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis.
Hamada Y; Seto Y; Yago K; Kuroyama M
J Infect Chemother; 2012 Aug; 18(4):501-7. PubMed ID: 22231601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
